The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized phase II trial comparing the efficacy and safety of nintedanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC).
 
Daniel H. Palmer
Honoraria - Bayer; Boehringer Ingelheim
Consulting or Advisory Role - Bayer; Boehringer Ingelheim
Speakers' Bureau - Bayer
 
Yuk Ting Ma
Research Funding - Bayer (Inst); Boehringer Ingelheim (Inst); Polaris (Inst)
Travel, Accommodations, Expenses - Bayer
 
Markus Peck-Radosavljevic
Honoraria - Bayer; Boehringer Ingelheim; Lilly; Novartis; Ontorii
Consulting or Advisory Role - Bayer; Boehringer Ingelheim; Lilly; Ontorii
Speakers' Bureau - Bayer; Lilly
Research Funding - Bayer; Boehringer Ingelheim; Lilly
Travel, Accommodations, Expenses - Bayer; Lilly
 
Paul J. Ross
Honoraria - Bayer; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Roche; Sanofi; Sirtex Medical
Consulting or Advisory Role - Bristol-Myers Squibb
Speakers' Bureau - Sirtex Medical
Research Funding - Sanofi
Travel, Accommodations, Expenses - Celgene; Merck Serono; Roche; Sanofi
 
Janet Shirley Graham
No Relationships to Disclose
 
Laetitia Fartoux
No Relationships to Disclose
 
Andrzej Deptala
Honoraria - Bayer; Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; Roche
 
Arne Wenz
Employment - Boehringer Ingelheim
 
Julia Hocke
Employment - Boehringer Ingelheim
 
Arsene-Bienvenu Loembe
Employment - Boehringer Ingelheim
 
Tim Meyer
No Relationships to Disclose